CA
NZ
UK
AU
IND
US
● MetaVia, a small Cambridge, Massachusetts biotech formerly known as NeuroBo Pharmaceuticals, is testing an obesity drug candidate that posted a 9.1% weight-loss signal in an early, uncontrolled cohort. A pivotal readout is still months away.
Zoetis Inc. (NYSE:ZTS) shares closed at $78.42, rising 1.2% despite a significant year-to-date decline of 37.7%. Investor sentiment remains weak as rising costs, including high interest rates and oil prices, continue to weigh heavily on the market outlook.Key HighlightsZoetis shares increased 1.2%, closing at …
Pulse Biosciences, Inc. has reached the midpoint of its NANOPULSE-AF clinical study, boosting investor confidence and contributing to a 155.8% year-to-date share price surge. The company's advancing technology for treating atrial fibrillation highlights significant potential in the healthcare market.Key HighlightsPulse Biosciences has surpassed the …
Synergy CHC Corp. reported a loss of $-0.23 in EPS, sharply missing the $0.04 consensus estimate. The company's ongoing challenges intensified following Costco's announcement to cease carrying its FOCUSfactor line, which significantly contributed to its revenue base.Key HighlightsSynergy CHC Corp. recorded an EPS of …
uniQure N.V. reported a net loss of $81.1 million, resulting in an earnings per share (EPS) of $1.22 for the quarter ending June 30, 2026. This substantial loss highlights rising operational costs and unexpected non-operating expenses, signaling potential challenges for the company moving forward.Key …
Spok Holdings, Inc. (NASDAQ: SPOK) has reported a net income of $4.1 million for the second quarter of 2026, maintaining its quarterly dividend at $0.3125 per share. This dividend is unchanged and aligns with prior declarations, reinforcing investor confidence amid earnings fluctuations. The company …
The Trump administration's decision to eliminate Medicare drug plan subsidies starting in 2027 could have widespread ramifications for the healthcare sector. The subsidy, currently supporting Medicare Part D, will no longer be available, leaving beneficiaries prone to higher out-of-pocket drug costs. This move is …
Xencor Inc (NASDAQ: XNCR) has secured a significant settlement, culminating in a total of $105 million. This figure marks one of the most substantial financial boosts in recent times for the clinical-stage biopharmaceutical company, which is focused on developing engineered antibodies for cancer and …
Kura Oncology, Inc. has undertaken significant leadership changes, revamping executive employment agreements intended to enhance retention and provide more favorable severance terms. On July 24, 2026, the company entered into a modified agreement with its Chairman, President, and CEO, which adjusts severance provisions to …
MIMEDX Group reported a net loss of $15 million for the second quarter, aligning with earlier expectations. The company sees growth in its surgical product line against a challenging backdrop in wound care. This signals continued volatility for investors, especially as MIMEDX pursues the …
Please wait processing your request...